

Cystinuria - Pipeline Insight, 2021

<https://marketpublishers.com/r/CD5C2CCCFA30EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CD5C2CCCFA30EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Cystinuria - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cystinuria Understanding

Cystinuria: Overview

Cystinuria is a rare genetic disorder that causes a buildup of an amino acid called cystine in the urine. This can result in the formation of cystine kidney stones. Cystine stones are often larger, harder and form more frequently than other kinds of kidney stones. Due to the larger stone size, cystine stones may be more difficult to pass, often requiring surgical procedures to remove. Stones can create blockages in the urinary tract and reduce the ability of the kidneys to eliminate waste through urine. The stones also provide sites where bacteria may cause infections. Signs and symptoms of the condition are related to the presence of stones and may include blood in the urine, flank pain, and frequent urinary tract infections.

'Cystinuria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Cystinuria pipeline landscape is provided which includes the disease overview and Cystinuria treatment guidelines. The assessment part of the report embraces, in depth Cystinuria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystinuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cystinuria R&D. The therapies under development are focused on novel approaches to treat/improve Cystinuria.

Cystinuria Emerging Drugs Chapters

This segment of the Cystinuria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cystinuria Emerging Drugs

Bucillamine: Revive Therapeutics

Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. The drug is in phase 2 of clinical trials for the treatment of cystinuria.

ADV 7103: Advicenne

ADV7103 is an investigational drug and has not yet been approved by any regulatory authority and is being developed by Advicenne. Advicenne Received Positive CHMP Opinion Recommending Approval of ADV7103 for the Treatment of Distal Renal Tubular Acidosis (dRTA). The drug is in phase II/III of clinical trials for the treatment of cystinuria.

Further product details are provided in the report.....

Cystinuria: Therapeutic Assessment

This segment of the report provides insights about the different Cystinuria drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cystinuria

There are approx. 3+ key companies which are developing the therapies for Cystinuria. The companies which have their Cystinuria drug candidates in the mid to advanced stage, i.e. phase II/III include, Advicenne and others.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cystinuria pipeline report provides the therapeutic assessment of the pipeline drugs by

the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cystinuria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystinuria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystinuria drugs.

Cystinuria Report Insights

Cystinuria Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cystinuria Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cystinuria drugs?

How many Cystinuria drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystinuria?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cystinuria therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cystinuria and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Revive Therapeutics

Advicenne

Key Products

Bucillamine

ADV 7103

Contents

Introduction

Executive Summary

Cystinuria: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Cystinuria – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Cystinuria companies' collaborations, Licensing, Acquisition -Deal Value Trends

Cystinuria Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II/III)

- Comparative Analysis

ADV 7103: Advicenne

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Bucillamine: Revive Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Cystinuria Key Companies

Cystinuria Key Products

Cystinuria- Unmet Needs

Cystinuria- Market Drivers and Barriers

Cystinuria- Future Perspectives and Conclusion

Cystinuria Analyst Views

Cystinuria Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cystinuria

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Cystinuria
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Cystinuria - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CD5C2CCCFA30EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD5C2CCCFA30EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970